Literature DB >> 10898710

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

H W Boucher1, C B Wennersten, G M Eliopoulos.   

Abstract

The in vitro activities of GAR-936, the 9-t-butylglycylamido derivative of minocycline, were compared with those of doxycycline, minocycline, and tetracycline against 527 gram-positive clinical isolates. GAR-936 inhibited all strains, including those resistant to other tetracyclines, at concentrations of </=2 microg/ml, except two strains of JK diphtheroids for which the MIC was 4 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10898710      PMCID： PMC90048          DOI： 10.1128/AAC.44.8.2225-2229.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Determinants of vancomycin use in adult intensive care units in 41 United States hospitals.

Authors:  S K Fridkin; J R Edwards; S C Pichette; E R Pryor; J E McGowan; F C Tenover; D H Culver; R P Gaynes
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

2.  Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines.

Authors:  B A Rasmussen; Y Gluzman; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 3.  Vancomycin-resistant enterococci. Mechanism and clinical relevance.

Authors:  G M Eliopoulos
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

Review 4.  Antimicrobial-drug resistance.

Authors:  H S Gold; R C Moellering
Journal:  N Engl J Med       Date:  1996-11-07       Impact factor: 91.245

5.  Problems with antimicrobial resistance in gram-positive cocci.

Authors:  R C Moellering
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

6.  In vitro activities of two glycylcyclines against gram-positive bacteria.

Authors:  G M Eliopoulos; C B Wennersten; G Cole; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  In-vitro activity of Sch 29482 in comparison with other oral antibiotics.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

8.  Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality.

Authors:  M B Edmond; J F Ober; J D Dawson; D L Weinbaum; R P Wenzel
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

9.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Nosocomial enterococci resistant to vancomycin--United States, 1989-1993.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1993-08-06       Impact factor: 17.586
View more
  34 in total

1.  In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  M D Kitzis; A Ly; F W Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.

Authors:  Emilia Cercenado; Sonia Cercenado; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

4.  Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 5.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.

Authors:  Peter J Petersen; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.

Authors:  C Hal Jones; Margareta Tuckman; Anita Y M Howe; Mark Orlowski; Stanley Mullen; Karen Chan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

9.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 10.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.